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ABSTRACT
CXB-2/By (CXB-2) recombinant inbred mice express a subset of the minor histocompatibility antigen (miHA)
repertoire expressed by C.B10-H2b/LiMcdJ (BALB.B) mice. On lethal irradiation and the transplantation of
H2b-matched C57BL/6 (B6) T cell–depleted bone marrow cells, along with naive unfractionated T cells, both
strains succumb to acute graft-versus-host disease (GVHD). Although alloreactive B6 CD4 T cells are a
necessary source of T-cell help for the B6 CD8 component of the GVHD response in both recipient strains,
they are capable of mediating severe GVHD by themselves only in BALB.B mice. Previous CD4 T-cell
receptor repertoire analysis demonstrated overlapping oligoclonal V use between the CD4 B6 anti-BALB.B
and B6 anti–CXB-2 responses, with indications of additional BALB.B unique T-cell responses (V2 and V11).
We report here that the more severe B6 anti-BALB.B response is not due to a quantitative difference in the
responding cells, because the frequency of alloreactive donor CD4 T cells over time was equivalent in the
spleens of BALB.B versus CXB-2 recipients. The responses were also similar in the number of infiltrating B6
CD4 T cells in the lingual epithelium of the 2 recipients. In contrast, a significantly greater degree of
infiltration and injury of BALB.B intestinal epithelium correlated with the increased level of clinical GVHD
severity. Of most significance, despite the involvement of at least 11 V-associated CD4 T-cell families in the
overall B6 anti-BALB.B response, the development of severe GVHD correlated with the presence of V2- and
V11-positive donor T cells. Transplantation of donor CD4 T cells from V-associated families that were
shared between the B6 anti-BALB.B and anti–CXB-2 responses resulted in minimal GVHD potential. These
data suggest that severe GVHD across miHA barriers depends on the involvement of a restricted number of
potent T-cell specificities and implies that there are only a limited number of corresponding responsible
miHAs.
© 2004 American Society for Blood and Marrow Transplantation
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tNTRODUCTION
Allogeneic hematopoietic cell transplantation
HCT) is used as therapy for many hematologic ma-
ignancies [1]. In major histocompatibility complex
MHC)–matched donor/recipient situations, T cells
n the stem cell inoculum can respond to host minor
istocompatibility antigens (miHA), which are MHC g
B&MTlass I–or II–presented peptides that originate from
ither ubiquitous or tissue-associated polymorphic
rotein products [2]. The positive aspects of this allo-
eactive response are that it can potentially target cells
f the host immune system and/or leukemic cells that
ave survived cytoreductive preconditioning and can
herefore enhance stem cell engraftment or provide a
raft-versus-leukemia effect, respectively [3-6]. These
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9mportant therapeutic beneﬁts have established the
recedence of allogeneic over autologous HCT pro-
edures [7,8]. However, the negative consequence of
his approach is the often-lethal effects of acute graft-
ersus-host disease (GVHD), which is due to the rec-
gnition of host miHA expressed in various tissues—
rimarily the skin, gastrointestinal tract, and liver
4,5,9,10]. Understanding the immunobiology of anti-
iHA GVHD is crucial for developing more speciﬁc
eans of providing an effective graft-versus-leukemia
esponse without provoking acute GVHD.
Experimentally, the potential of either CD4 or
D8 donor T cells to mediate GVHD across a
iHA barrier depends on the particular donor/recip-
ent combination being investigated [11-14]. Overall,
D4 T cells are much more limited in their capacity
o mediate lethal GVHD than CD8 T cells [11,12].
uch observations have also been borne out in clinical
rials that have involved the selective depletion of
onor CD8 T cells to lessen the risks of GVHD
15-17]. It is interesting to note that in the mouse
odels in which lethal acute CD4-mediated anti-
iHA GVHD did occur, it correlated neither with
rimary CD4 proliferative responses in mixed lym-
hocyte reactions (MLR) in vitro nor with known
uperantigen differences between the strains [11]. De-
ermining the factors that inﬂuence the immuno-
athogenesis of CD4 T cell–mediated GVHD will
elp to better anticipate and prevent its clinical devel-
pment, especially in the context of selective CD8
-cell depletion.
The transplantation of H2b-matched C57BL/6
B6) bone marrow and CD4 T cells into lethally
rradiated C.B10-H2b (BALB.B) recipients is one such
odel in which donor CD4 T cells alone can cause
ethal GVHD [13]. However, when one substitutes
he recipient mice with the H2b CXB-2 recombinant
nbred strain, originally derived from crosses between
ALB/c and B10 progenitor mice [18], CD4-medi-
ted GVHD of any consequence fails to develop,
espite the fact that CD4 cells are required to provide
elp for an effective CD8-mediated response [13].
ecause the CXB-2 strain expressed a subset of the
otal BALB.B miHA capacity, of which the quantity
nd identity are unknown, we initially approached the
ypothesis that the variation in CD4-mediated
VHD severity between the 2 strains would be re-
ected in the scope and heterogeneity of the individ-
al alloreactive T-cell repertoires. Thus, T-cell recep-
or (TCR) V CDR3-size spectratype analysis was
sed to compare the early in vivo B6 CD4 anti-
ALB.B and anti–CXB-2 responses [19]. This analysis
evealed that of the 11 different V families involved
n the B6 anti-BALB.B response, 9 were also impli-
ated in the anti–CXB-2 response, thus suggesting a
igh degree of overlap between the 2 miHA-driven
esponses. The 2 CD4 V family–associated re- p
2ponses consistently observed in only the BALB.B
ecipients were within the V2 and V11 families and
aised the question of whether these particular re-
ponses were involved in the increased severity of
VHD in those mice. In this study, we investigated
he relationship between B6 V2 and V11 T cells
ith severe GVHD development and other factors
hat might be responsible for the level of immunopa-
hology observed in BALB.B recipients. We found
hat severe disease is not due to a quantitative differ-
nce in the clonal frequency of responding allogeneic
6 CD4 T cells but does seem to correlate with the
peciﬁc involvement of these unique, potent GVHD-
ausing T-cell speciﬁcities.
ATERIALS AND METHODS
ice
BALB.B, CXB-2/By (previously denoted as
XBE), B6, and RAG 1/ B6 mice, all of the H2b
aplotype, were purchased from the Jackson Labora-
ory (Bar Harbor, ME) or raised in our breeding
olony. For all experiments, sex-matched mice be-
ween the ages of 7 and 14 weeks were used as donors
nd recipients. Mice were housed in a pathogen-free
nvironment in autoclaved microisolator cages and
ere provided with autoclaved water and food ad
ibitum.
onoclonal Antibodies
Ascities ﬂuid containing anti–Thy-1.2 (J1j; rat im-
unoglobulin [Ig]M [20]) and anti-CD8 (3.168; rat
gM [21]) monoclonal antibodies (mAb) were used
long with guinea pig complement (C; Rockland,
oyertown, PA) for cell subset depletions. Afﬁnity-
uriﬁed goat anti-mouse IgG antibody (Cappel-Or-
anon Teknika, West Chester, PA) was used for B-cell
anning. The following mAbs were purchased from
harmingen (San Diego, CA): phycoerythrin (PE) or
iotin-conjugated anti-CD3, CD4, CD8, B220,
D25, CD69, V3, Ly9.1, and negative isotype con-
rols; ﬂuorescein isothiocyanate (FITC)–conjugated
nti-V2, 5, 10, 11, and 12; and PE-Cy5 (Cy-
hrome)–conjugated anti-CD4 and its negative iso-
ype control. PE-Cy5 (Tri-Color)-conjugated anti-
D4 mAb was purchased from Caltag (Burlingame,
A). Puriﬁed anti-CD3 mAb was purchased from
ntigenix America (Franklin Square, NY).
reparation of Donor Cells
Phosphate-buffered saline (PBS; BioWhittaker,
alkerville, MD) supplemented with 0.1% bovine
erum albumin (BSA; Sigma Chemical, St. Louis,
O) was used for all preparative manipulations of the
onor bone marrow and lymphocytes. T cell–de-
leted (anti–Thy-1.2 mAb treated) bone marrow
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V-Associated Anti-miHA CD4 T-Cell Responses
BATBM) was prepared by ﬂushing bone marrow cells
rom the femurs and tibiae of either donor RAG 1/
6 mice or normal B6 mice, followed by incubation
ith J1j mAb (1:50 dilution) and C (1:12 dilution) for
5 minutes at 37°C. T cell–enriched donor cells were
repared from pooled spleen and lymph node (LN)
ell suspensions from naive or appropriate host-pre-
ensitized B6 mice that were primed and then boosted
ith either BALB.B or CXB-2 spleen cells (1.5-2 
07 cells; intraperitoneal injections, 2 weeks apart), as
reviously described [19]. Brieﬂy, after red blood cell
ysis with Gey balanced salt solution containing 0.7%
H4Cl, B cells were removed by panning the cell
uspension over goat anti-mouse IgG–coated plastic
etri dishes for 1 hour at 4°C. For CD4 subset en-
ichment, nonadherent lymphocytes were depleted of
D8 T cells by incubation with 3.168 mAb (1:50
ilution) and C (1:12 dilution) for 45 minutes at
7°C. Donor T cells were 97% CD4, as deter-
ined by ﬂow cytometry. For V family enrichment
r depletion, after the labeling of donor CD4 T cells
ith appropriate FITC-conjugated anti-V mAb,
ells were incubated with immunomagnetic cell-sort-
ng anti-FITC microbeads (Miltenyi Biotec, Berisch-
ladbach, Germany). Labeled cells were then posi-
ively selected by the Vario-MACS column system per
he manufacturer’s instructions (Miltenyi). The purity
f positively selected V cells ranged from 82.9% to
9.6%. The possibility of nonspeciﬁc activation by the
election process was excluded by testing the in vitro
roliferative activity of these T cells after selection
ith V-speciﬁc mAb (including anti-V11), without
ny additional stimulus. We observed equivalent, if
ot lower, activity than unfractionated T cells (Patter-
on and Korngold, unpublished data). V-depleted
ells did not stain signiﬁcantly above background for
he V family of interest. All cells were injected in-
ravenously in PBS.
LR Culture
CD4 enriched T cells were prepared as described
reviously from naive or appropriate host-presensi-
ized B6 mice. Respective T-cell populations were
hen placed into culture (2  105 per well) in RPMI
640 media supplemented with 2 mmol/L l-glu-
amine, 50 IU/mL penicillin, 50 	g streptomycin (all
rom Mediatech, Herndon, VA), 10% fetal calf serum
Sigma Chemical), and 2-mercaptoethanol (Life
echnologies, Grand Island, NY), along with irradi-
ted (20 Gy) recipient-type splenocytes (4  105) at
7°C in 7% CO2. Proliferation was assessed at the
ndicated time point by pulsing with 1 	Ci per well
3H]thymidine (TdR) for 8 hours and measuring the
ncorporation levels from harvested cells with a model
205 Betaplate Counter (Wallac, Turku, Finland). B
B&MTata were expressed as the mean [3H]TdR incorpo-
ation counts per minute.
-Carboxyfluorescein Diacetate Succinimidyl Ester
abeling and In Vivo Quantitation
T cell–enriched B6 spleen and LN cells were
repared as described previously and resuspended in
BS at 2.5 107 cells per milliliter. Cells were labeled
ith 5-carboxyﬂuorescein diacetate succinimidyl ester
CFSE; Molecular Probes, Eugene, OR) at a ﬁnal
oncentration of 1.5 	mol/L for 10 minutes at 37°C,
imilar to previously described methods [22]. The
abeling was brought to an immediate halt by the
ddition of cold RPMI media containing 10% fetal
alf serum, followed by 2 additional washes in PBS.
ALB.B, CXB-2, and syngeneic control B6 mice were
ethally irradiated (13 Gy; split dose at 1.36 Gy/min)
y exposure from a Mark-1 Model 68 cesium 137
ource (J.L. Shepherd, San Fernando, CA) and in-
ected 3 to 4 hours later with the prepared CFSE-
abeled donor cells (3-4  107 cells per mouse).
Mice were killed 2 to 5 days later, and spleens and
eripheral LNs were harvested and processed to a
ingle-cell suspension. Dead cells were removed by
ympholyte M centrifugation (Cedar Lane Laborato-
ies, Ontario, Canada) per the manufacturer’s instruc-
ions. All cell populations were initially incubated with
nti-FcR
II mAb (clone 2.4G2; American Type Cul-
ure Collection, Rockville, MD) to block FC recep-
ors, followed by the addition of appropriate ﬁrst-layer
Abs for ﬂow cytometric analysis. When applicable,
his was followed by the addition of streptavidin (SA)/
E, SA/PE-Texas red, or SA/PE-Cy5 (Tri-Color; all
rom Caltag). All washes were with PBS containing
% BSA and 0.01% NaN3. Cells were either analyzed
mmediately or ﬁxed in 1% paraformaldehyde (Elec-
ron Microscopy Sciences, Ft. Washington, PA) for 15
inutes at 4°C, followed by a ﬁnal wash. Fluorescence
nalysis was performed on an XL-MCL analytic cy-
ometer (Beckman Coulter, Miami, FL). Live lym-
hocytes were determined by forward- and side-scat-
er properties, and gate parameters were set to exclude
ackground isotype-control mAb binding and back-
round overlap in ﬂuorescence emission between
uorochromes in the case of multiple color staining. A
otal of 1.5 to 3  105 events were collected per
ample. The determination of gates for dividing B6
Ly9.1) CFSE-labeled CD4 donor T cells was
ased on the exclusion of residual BALB.B host
Ly9.1) CD4 cells, and these were limited to 6
ivisions.
alculation of Frequency of Proliferating T Cells
n Vivo
The clonal frequency of proliferating allogeneic
6 CD4 T cells in vivo was determined as previously
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9escribed [22,23]. Distinct rounds of cell division were
dentiﬁed by CFSE division proﬁles in histogram for-
at, and gates demarking individual division peaks
ere analytically determined on the basis of the me-
ian ﬂuorescence intensity of the undivided peak. The
umber of CD4 CD25T cells in each division peak
as counted with the WinMDI Flow Cytometry Ap-
lication (J. Trotter, Scripps Research Institute, La
olla, CA), and the number of clonal precursors that
nitially divided to give rise to the total number of
aughter cells per division was extrapolated by using
he formula
x/2n,
here x equals the number of cells in each division
nd n equals the division number. The frequency of
ctivated alloreactive CD4 T cells in the donor pop-
lation was calculated by dividing the number of
lonal precursors by the total of all precursors and
ndivided cells. B6 CD4 T-cell allogeneic response
requencies were not signiﬁcantly different after the
njection of either CD4-enriched or unseparated T
ells. Thus, to reduce cell manipulation, experiments
ere performed with unseparated T-cell preparations.
VHD Assay
BALB.B and CXB-2 recipients were lethally irra-
iated (10 or 13 Gy; split dose; 4 hours apart) and were
njected intravenously 3 to 4 hours later with 1 to 2 
06 B6 ATBM cells alone or in combination with the
ndicated numbers of naive, host-presensitized, or V
amily–enriched B6 CD4 T cells. To determine
hether individual V families represented a signiﬁ-
ant contributing component of the observed
63BALB.B CD4 GVHD response, V family–en-
iched CD4 T-cell doses were based on their relative
umber in the control CD4 T-cell injection [24].
his allowed for the direct comparison of disease
everity between V family–selected and unseparated
D4 recipients. Animals were monitored for morbid-
ty and mortality and weighed regularly until the ter-
ination of the experiment.
mmunohistochemistry
Immunohistochemistry was performed as previ-
usly described [25]. Brieﬂy, the tongue, liver, and
istal ileum were removed and cryopreserved by em-
edding in O.C.T. freezing compound (Miles Labo-
atories, Elkhart, IN), snap-frozen in liquid nitrogen,
nd stored at 80°C. Cryostat sections (5 	m thick)
ere air-dried, ﬁxed in acetone, and incubated with
ormal rabbit serum for 20 minutes at room temper-
ture. Sections were then incubated for 1 hour at
oom temperature or overnight at 4°C with appropri-
te puriﬁed rat anti-mouse mAb and diluted in PBS i
4upplemented with 0.1% BSA and 0.1% NaN3. Afﬁn-
ty-puriﬁed biotinylated rabbit anti-rat polyclonal an-
ibody was then layered on each section for 30 minutes
t room temperature, followed by the addition of
reformed Vectastain Elite avidin-biotin-peroxidase
Vector Labs, Burlingame, CA) for an equal time.
mmunoreactivity was revealed by using either 3,3-
iaminobenzidine tetrahydrochloride (Sigma Chemi-
al) or VIP (Vector) substrates. After a brief rinse in
istilled water, sections were counterstained with
ayer hematoxylin and then dehydrated and cover-
lipped. All washing steps were performed with PBS
lone. Enumeration of inﬁltrating CD4 T cells was
erformed under 200 to 400 magniﬁcation.
erminal Deoxynucleotidyl Transferase–Mediated
eoxyuridine Triphosphate Nick-End Labeling
nalysis
Detection of apoptosis by the terminal deoxynu-
leotidyl transferase–mediated deoxyuridine triphos-
hate nick-end (TUNEL) technique was performed
s previously described [26] by using an Apoptag per-
xidase kit (Serologicals, Norcross, GA). Brieﬂy,
-	m cryostat sections were ﬁrst ﬁxed in cold 4%
araformaldehyde, followed by treatment with etha-
ol/acetic acid solution. Sections were then equili-
rated and reacted with either terminal deoxynucleo-
idyl transferase (TdT) in reaction buffer containing
igoxigenin-labeled uridine triphosphate (UTP) or
uffer alone, followed by peroxidase-labeled anti-
igoxigenin antibody (Apoptag kit). Labeled double-
tranded DNA breaks were then detected with either
,3-diaminobenzidine tetrahydrochloride or VIP
hromagens, followed by counterstain with methyl
reen (BioGenex, San Ramon, CA).
tatistical Analysis
Mid survival times (MST) for bone marrow–trans-
lanted animals were calculated as the extrapolated
0% survival point of a linear regression through all of
he death data points, including 0. Statistical compar-
sons of survival data between experimental groups
ere based on individual days of death and were per-
ormed by the nonparametric Wilcoxon signed rank
est. Weight data were expressed as the mean percent-
ge of initial body weight during sequential 1-week
eriods after transplantation. Signiﬁcance for weight
omparisons and all other data between groups was
etermined by the Student t test. For all statistical
nalysis, P  .05 was considered to be signiﬁcant.
ESULTS
VHD Potential of Host-Presensitized B6 CD4
Cells
We have previously demonstrated that lethally
rradiated BALB.B recipients transplanted with
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V-Associated Anti-miHA CD4 T-Cell Responses
BTBM and naive B6 CD4 T cells experience acute
ethal GVHD, whereas identically preconditioned
XB-2 recipients undergo only minimal disease [13].
o further examine the susceptibility to B6 CD4 T
ell–mediated GVHD, BALB.B and CXB-2 recipients
ere lethally irradiated (as described in Materials and
ethods) and injected with 2 106 ATBM cells along
ith either 2 107 naive B6 CD4T cells or an equal
umber of CD4 T cells from B6 mice that had been
resensitized with either BALB.B or CXB-2 spleno-
ytes, respectively. Consistent with previous observa-
ions, the transfer of 2  107 naive B6 CD4 T cells
nto BALB.B recipients resulted in lethal GVHD
MST, 58 days; Figure 1A), and the survivors exhib-
ted signiﬁcant cachexia for the duration of the exper-
ment (P  .001 versus ATBM alone; Figure 1B). In
arked contrast, CXB-2 recipients of 2  107 naive

igure 1. GVHD potential of naive versus host-presensitized B6 CD
XB-2 mice were lethally irradiated and injected with 2  106 B6
r appropriately host-presensitized (C and D) B6 CD4 T cells. A
roup normalized as the mean  SEM percentage of initial body w
rom 3 separate experiments, and data for C and D were from a sing
6 CD4 T cells were cultured in duplicate for 3 days with irradiat
timulator) and pulsed with [3H]TdR for the last 8 hours of culture.
inute (CPM) and were consistent with trends from an enzyme-li6 CD4 T cells experienced only minor GVHD r
B&MTortality (MST of 90 days), with no signiﬁcant
achexia until week 8 after HCT (P  .02 versus
TBM alone), after which point there was no weight
oss for the remainder of the experiment (P  .06).
The injection of 2  107 BALB.B-presensitized
6 CD4 T cells led to increased GVHD severity in
ethally irradiated BALB.B recipients, achieving 100%
ortality by day 48 after HCT (MST, 30 days; Figure
C). However, despite causing signiﬁcant GVHD-
ssociated cachexia during weeks 5 to 10 after trans-
lantation (P  .014 versus ATBM alone; Figure 1D),
XB-2–presensitized B6 CD4 T cells remained in-
apable of mediating a lethal level of disease in CXB-2
ecipients (MST, 80 days; Figure 1C). This lack of
evere GVHD was not due to ineffective host presen-
itization of B6 donors by CXB-2 splenocytes, because
 107 BALB.B-primed B6 CD4 T cells similarly
cells transplanted into BALB.B and CXB-2 recipients. BALB.B and
cells alone or in combination with either 2  107 naive (A and B)
, Survival of transplant recipients. B and D, Body weights for each
uring sequential 1-week periods. Data for A and B were combined
esentative experiment. E, Naive or appropriately host-presensitized
Gy) BALB.B, CXB-2, or B6 splenocytes (1:2 ratio of responder to
ere expressed as mean  SEM [3H]TdR incorporation counts per
munospot (ELISPOT) assay run in parallel (data not shown).4 T
ATBM
and C
eight d
le repr
ed (20
Data wesulted in minimal GVHD lethality in CXB-2 recip-
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9ents (MST, 80 days; Figure 1C), nor was weight
oss more severe in these recipients at any time com-
ared with the infusion of CXB-2–primed B6 CD4
cells (Figure 1D). Effective host presensitization
as also demonstrated in vitro, because B6 CD4 T
ells from mice similarly primed against either
ALB.B or CXB-2 splenocytes both demonstrated
ncreased levels of proliferation in comparison to na-
ve B6 CD4 T cells on stimulation with the respec-
ive host-type splenocytes in an MLR assay (Figure
E).
63BALB.B versus B63CXBE CD4 T-Cell
lloreactive Clonal Response Frequencies In Vivo
Because the probability of developing GVHD cor-
elates with the strength of the histoincompatibility
etween donor and host [9] and because CXB-2 mice
xpress only a subset of BALB.B miHA, we investi-
ated whether the increased severity of GVHD in the
ALB.B recipients could be due to a greater clonal
requency of anti-miHA alloreactive B6 CD4 T
ells. To quantitatively compare the 2 responses in
ivo, CFSE-labeled naive B6 T cells were injected into
ethally irradiated BALB.B, CXB-2, and B6 mice.
FSE is a ﬂuorescent cytoplasmic dye that distributes
qually between daughter cells on division, resulting
n a halving of a cell’s ﬂuorescence intensity that can
e visualized by ﬂow cytometry [23]. At serial time
oints after injection, CFSE-labeled cells were recov-
red from the spleens and co-stained with anti-CD4
nd anti-Ly9.1 mAb, the latter to distinguish any
D4 cells of BALB.B (Ly9.1) origin.
Donor CD4 T cells underwent as many as 4
ounds of proliferation within 48 hours, reached the
ear limit of detection with 6 rounds of division by 68
ours, and continued to proliferate through 115 hours
fter infusion into both BALB.B and CXB-2 recipi-
nts (Figure 2A). Quantitative analysis of the prolif-
rating B6 CD4 T cells normalized to the nonspe-
iﬁc B63B6 CD4 T-cell control response reﬂected
n increased percentage of dividing cells over time,
ith proliferation in CXB-2 recipients similar to or
reater than that found in BALB.B mice (48 hours,
 .11; 68 hours, P .05; 115 hours, P .27; Figure
B).
To clearly discern between antigen-driven and
omeostatic proliferation on injection of the B6
D4 T cells into irradiated recipients, CFSE
D4 donor cells were co-stained for the IL-2 recep-
or -chain (CD25), an activation marker [27,28].
imilar to observations in an MHC-disparate lethal
rradiation model [28], expression of CD25 by a co-
ort of donor CD4 T cells was evident in both
ALB.B and CXB-2 recipients by 68 hours after in-
usion (Figure 3A).
The clonal frequencies of dividing alloreactive B6
 D4 CD25 T cells in harvested spleens of BALB.B t
6nd CXB-2 recipients were then calculated (see Ma-
erials and Methods) and were normalized against the
onspeciﬁc response frequency in syngeneic B6 recip-
ent spleens. There were insufﬁcient numbers of di-
iding CD4 CD25 T cells at 48 hours for accurate
requency analysis. However, division at 68 hours after
nfusion revealed mean alloreactive frequencies of 96
nd 102 per 105 CD4T cells for the B6 anti-BALB.B
nd anti–CXB-2 responses, respectively (P  .41; Fig-
re 3B). Equivalent increases in these frequencies
ere noted at 115 hours in both recipient strains,
eaching approximately 280 clonal cells per 105 cells
P  .89). Frequency calculations based on B6 CD4
D25 or CD69 T-cell division at 115 hours in
ALB.B or CXB-2 peripheral LN yielded frequency
esults similar to those of the splenic populations (data
ot shown).
Because both BALB.B and CXB-2 strains express
he mouse mammary tumor virus (MMTV-6) super-
ntigen, which is known to induce proliferation of B6
D4 V3 T cells [24], the contribution of these
ells to the overall alloresponse frequency at 68 hours
fter infusion was determined by 4-color ﬂow cyto-
etric analysis. Dividing CD4 CD25 V3 T cells
ccounted for 15.8% and 22.6% of the B6 CD4
nti-BALB.B and anti–CXB-2 response frequencies,
espectively (Figure 3C). Thus, the similarity of the
3 response frequency between the 2 recipient
trains did not seem to account for the more severe
evel of GVHD observed in the BALB.B recipients.
VHD Target Tissue Infiltration and Injury
To evaluate the immunopathologic effects of the
esponding B6 anti-BALB.B and anti–CXB-2 CD4
-cell populations, lethally irradiated recipients were
njected with 2  106 ATBM cells along with 2  107
aive B6 CD4 T cells and killed on day 30 after
CT for target organ harvest and quantitative CD4
-cell immunohistologic analysis. Evaluation focused
n the skin (lingual epithelium) and gut (distal ileum),
he major target organ sites in these strain combina-
ions. Consistent with the equivalent B6 CD4 T-cell
roliferative response in BALB.B and CXB-2 lym-
hoid compartments, CD4 T-cell inﬁltration into
he lingual epithelium was equally aggressive in both
ecipients (Figure 4A, B, and G; P  .39). Detailed
bservation revealed preferential CD4 T-cell traf-
cking in the BALB.B and CXB-2 lingual epithelium
o the suprabasal region of the epithelial ridges—areas
hought to contain epithelial stem cells preferentially
argeted in GVHD [29-31]. As expected, syngeneic
ontrol B6 recipients demonstrated a very minor de-
ree of CD4 T-cell inﬁltration (Figure 4C and G;
 .02 versus allogeneic combinations).
Previous work has demonstrated that apoptosis ishe principal form of epithelial target cell injury in
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V-Associated Anti-miHA CD4 T-Cell Responses
Bxperimental acute GVHD and that TUNEL staining
erves as a reliable indicator of this injury [26,32].
iffuse TUNEL-positive injury was found in both
ALB.B and CXB-2 recipient lingual epithelium,
ost notably in those lowermost epithelial layers
eavily inﬁltrated by donor lymphocytes (Figure 4D
nd E). Overall, BALB.B recipients had a nonsigniﬁ-
antly increased TUNEL-positive cell count com-
ared with CXB-2 mice (Figure 4H; P .10), whereas
oth groups had signiﬁcantly more epithelial apopto-
ic injury than B6 syngeneic recipients (P  .01).
In contrast to the lingual epithelium, CD4T-cell
nﬁltration of the BALB.B intestinal ileal crypts was
igniﬁcantly increased over that in the CXB-2 recipi-
nts (Figure 5A, B, and G; P  .05), which neverthe-
igure 2. B6 CD4 T-cell proliferative responses in vivo. BALB.B
njected with CFSE-labeled naive B6 T cells (3-4  107). Mice
istograms of B6 CD4 T-cell division in recipient spleens, as visua
, Percentage of B6 CD4 T cells having undergone up to 6 round
ombined from 7 individual experiments. No signiﬁcant differences
8 hours, P  .05; 115 hours, P  .27).ess still had signiﬁcantly more crypt-inﬁltrating w
B&MTD4T cells than B6 syngeneic recipients (P .003).
UNEL-positive cell counts followed the trend of
-cell inﬁltration, with a marginally signiﬁcant in-
rease in BALB.B recipients (P  .07 compared with
XB-2 mice; Figure 5H). It is important to note that
educed intestinal inﬂammation in CXB-2 recipients
as not due to less preconditioning regimen–related
ut injury, because the distal ileum from both strains
ad equally large numbers of apoptotic intestinal ep-
thelial cells at 4 and 24 hours after lethal irradiation
data not shown).
ffect of TCR Repertoire Selection on GVHD
everity
Using TCR V CDR3-size spectratype analysis,
2, and B6 syngeneic control recipients were lethally irradiated and
mpled at 48, 68, or 115 hours after infusion. A, Representative
y 2-color ﬂow cytometry of live-gated CFSE CD4 lymphocytes.
ision minus nonspeciﬁc B63B6 CD4 T-cell division. Data were
served between BALB.B and CXB-2 recipients (48 hours, P  .11;, CXB-
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were obe previously demonstrated that of the 11 V families
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9mplicated in the B6 CD4 anti-BALB.B T-cell re-
ponse, taken from the thoracic duct lymphocyte
TDL) pool 5 days after transplantation, all but 2
V2 and V11) were shared in the anti–CXB-2 re-
ponse as well [19]. V2 and V11 utilization may,
herefore, deﬁne miHA-speciﬁc T cells that are criti-
igure 3. B6 CD4 T-cell alloresponse frequency in vivo. These a
, Representative mean percentage CD25 expression by B6 CD4
ive-gated CFSE CD4 lymphocytes. There was no difference in
t both 68 and 115 hours, BALB.B and CXB-2 recipients were equ
ecipients (P .05). B, B6 CD4T-cell clonal allogeneic response fr
cells, minus the nonspeciﬁc B63B6 CD4 T-cell response frequ
XB-2 recipients, P .4 at all time points). C, Superantigen-stimula
s visualized by 4-color ﬂow cytometry of V3 dividing CFSE Cal for eliciting severe GVHD. To determine their l
8VHD potential, naive B6 CD4T cells enriched for
2 and V11 were injected along with 2  106
TBM cells into lethally irradiated BALB.B recipi-
nts. The dosage of V2- and V11-enriched T cells
njected (1.1  106) reﬂected their relative number in
he control 2  107 unseparated CD4 T-cell inocu-
were performed on the same cell samples as described in Figure 2.
ls in recipient spleens, as visualized by 3-color ﬂow cytometry of
expression among all groups at the 48-hour time point. However,
to each other (P  .05) but signiﬁcantly greater than syngeneic B6
y as determined by absolute numbers of CD25 dividing B6 CD4
ata were combined from 7 individual experiments (BALB.B versus
ponent of allogeneic response frequency at 68 hours after infusion,
CD25 T cells. Data are from a single experiment.nalyses
T cel
CD25
ivalent
equenc
ency. D
ted com
D4um (see Materials and Methods). Of most signiﬁ-
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V-Associated Anti-miHA CD4 T-Cell Responses
Bance, BALB.B recipients of these V2- and V11-
nriched donor cells succumbed to acute GVHD
MST, 46.8 days) with kinetics similar to those of
ecipients of 2  107 unseparated CD4 T cells
MST, 41.6 days; P  .14; Figure 6A). However,
ecipients of 2  107 V2- and V11-depleted cells
xperienced only 22% GVHD mortality (MST, 88
ays), although prolonged weight loss was observed
rom week 2 after HCT to the conclusion of the
xperiment (P  .004 versus ATBM only; Figure 6B).
s expected, CXB-2 recipients of V2- and V11-
nriched B6 CD4 T cells experienced no GVHD
ortality and only transient weight loss (P  .06
ersus ATBM alone, all weeks except 2, 5, and 6; P 
03; Figure 6A and B), consistent with their lack of
lonal expansion in the TDL of CXB-2 recipients, as
llustrated by previous spectratype analyses [19].
To conﬁrm that V2 and V11 B6 CD4 T
ells represented a uniquely potent GVHD-causing
opulation in BALB.B recipients, we investigated

igure 4. GVHD-associated CD4 T-cell inﬁltration and injury o
ethally irradiated BALB.B (A), CXB-2 (B), and syngeneic control B
aive B6 CD4 T cells and killed at day 30 after HCT. Note the di
idges in both BALB.B and CXB-2 recipient tissue; this was relative
ound in the lowermost epithelial regions of both BALB.B (D) an
yngeneic epithelium (F). G, Quantitative comparison of CD4 T-
ersus B6 syngeneic control, P  .02). H, TUNEL-positive injury
10; allogeneic combinations versus B6 syngeneic control, P  .01).
xperiment; n  3 to 4 for all groups (magniﬁcation in A-F, 400hether another set of V-enriched CD4 T cells, a
B&MT10 and V12, that were found responsive in
oth the BALB.B and CXB-2 recipients [19], would
lso be capable of mediating signiﬁcant disease. As
xpected, lethally irradiated CXB-2 recipients injected
ith 8.6  105 V10- and V12-enriched B6 CD4
cells had 100% survival (Figure 7A), although there
as a modest level of weight loss throughout the
uration of the experiment (P  .05 versus ATBM-
lone CXB-2 recipients; Figure 7B). Consistent with
hese results, V10- and V12-cell–transplanted
ALB.B mice experienced minimal GVHD-associ-
ted mortality (71.4% survival) compared with un-
eparated CD4 recipients (36.4% survival; P  .02).
owever, acute weight loss was noted early on,
eaked at week 6 after HCT, and then continued to
mprove afterward, but still remained below that of
he ATBM control group (P  .003 for weeks 2-15).
inally, BALB.B recipients injected with 5.2  105
5-enriched CD4 T cells, a V family previously
ound to be uninvolved in the B6 anti-BALB.B and
gual epithelium. CD4 T-cell inﬁltration of lingual epithelium of
ice transplanted with 2  106 B6 ATBM cells along with 2  107
D4 T-cell inﬁltration along the suprabasal region of the epithelial
nt in B6 recipients. Large, polyhedral TUNEL-positive cells were
-2 (E) recipients, with only rare apoptotic events noted in the B6
ltration (BALB.B versus CXB-2, P  .39; allogeneic combinations
ear millimeter (Lmm) of epithelium (BALB.B versus CXB-2, P 
resented were the mean  SEM levels of inﬁltration from a singlef the lin
6 (C) m
ffuse C
ly abse
d CXB
cell inﬁ
per lin
Data pnti–CXB-2 alloresponses by spectratype analysis of
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1DL [19], did not experience any GVHD-related
ortality. Moreover, acute weight loss was not ob-
erved within 2 months after HCT. It is important to
ote that to ensure lack of GVHD involvement, the
ose of V5 cells transplanted reﬂected twice the
umber found in the unseparated CD4 inoculum. The
ack of a V5-mediated GVHD response also sug-
ested that the positive-selection enrichment protocol
id not result in nonspeciﬁc activation. In summary, as
ompared with the V10 and V12 families involved
n both the anti-BALB.B and nonlethal anti–CXB-2
esponses, as well as the nonreactive V5 family, V2-
nd V11-enriched T cells had unique, severe GVHD–
ediating potential.
ISCUSSION
The activation and proliferation phase of GVHD
s driven by alloantigens presented by host antigen-
resenting cells and is required for the subsequent
evelopment of acute disease [33,34]. In this study, the
igure 5. GVHD-associated CD4 T-cell inﬁltration and injury o
rradiated BALB.B (A), CXB-2 (B), and syngeneic control B6 (C) m
6 CD4 T cells and killed on day 30 after HCT. Note the trend o
ersus CXB-2 recipients, with relatively fewer CD4 T cells found
leal crypts of BALB.B (D) versus CXB-2 (E) recipients, consistent w
nﬁltration (BALB.B versus CXB-2, P  .05; allogeneic combination
er 25 cross-sectional ileal crypts (BALB.B versus CXB-2, P  .0
resented were the mean  SEM levels of inﬁltration from a singlnitial B6 anti-BALB.B and anti–CXB-2 alloresponse o
00requency and kinetics were determined by infusion of
aive CFSE-labeled B6 CD4 T cells into lethally
rradiated recipients. An increase in the T-cell clonal
esponse frequency was detectable in both allogeneic
ecipients within 2 to 5 days (Figures 2 and 3), as
reviously observed in a similar model [35], and likely
eﬂects the sequestration and enrichment of prolifer-
ting alloreactive cells in the lymphoid organs, as
eported by Sprent and Miller [36] and Sprent and
efkovits [37]. Most importantly, we found that the
lonal response frequency based on the division of B6
D4 CD25 T cells was equivalent between
ALB.B and CXB-2 recipients at both 68 and 115
ours after transplantation and thus did not account
or the contrast in the level of GVHD severity in the
mouse models. Furthermore, as previously observed
24], we found a strong MMTV-6 superantigen–stim-
lated response of V3 B6 CD4 T cells in both
ALB.B and CXB-2 recipients. Although in other
urine studies, donor CD4 T-cell responses to
MTV were thought to be important for the devel-
istal ileum. CD4 T-cell inﬁltration of the ileal crypts of lethally
nsplanted with 2  106 B6 ATBM cells along with 2  107 naive
r CD4 T-cell inﬁltrates (arrows) in the ileal crypts (c) of BALB.B
eneic tissue. TUNEL-positive cells were more often noted in the
ell inﬁltration trends. (G) Quantitative comparison of CD4T-cell
s B6 syngeneic control, P  .003) and (H) TUNEL-positive injury
eneic combinations versus B6 syngeneic control, P  .02). Data
iment; n  3 to 4 for all groups (magniﬁcation in A-F, 400).f the d
ice tra
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in syng
ith T-c
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7; allogpment of GVHD immunopathology [38,39], the re-
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V-Associated Anti-miHA CD4 T-Cell Responses
Bponse did not correlate with the occurrence of severe
VHD in BALB.B mice, which exhibited a V3
-cell component equivalent to that in CXB-2 recip-
ents (Figure 3C).
The failure to progress to severe GVHD in
XB-2 recipients does not seem to be explained by
nadequacies in the inﬂammatory environment cre-
ted by the irradiation preconditioning regimen, nor
oes the induction of T-cell anergy seem to be re-
ponsible. First, B6 CD4 T cells are unable to me-
iate lethal GVHD in CXB-2 recipients precondi-
igure 6. GVHD potential of B6 anti-BALB.B V2 and V11
D4 T-cell responses. BALB.B and CXB-2 mice were lethally
rradiated and injected with 2  106 B6 ATBM cells alone or in
ombination with 2  107 unseparated B6 CD4 T cells, an equal
umber of V2- and V11-depleted (V2/11) CD4 T cells, or
.1 106 V2- and V11-enriched (V2/11) CD4T cells (mean
urity, 91%). A, Survival of transplanted recipients (BALB.B CD4
ersus BALB.B V2/11, P  .14). B, Body weights for each group
ormalized as the mean  SEM percentage initial body weight
uring sequential 1-week periods (BALB.B V2/11 versus
ALB.B ATBM, P  .004 weeks 2-13; CXB-2 V2/11 versus
XB-2 ATBM, P  .06 for all weeks except 2, 5, and 6, P  .03).
ata were combined from 2 similar experiments.ioned with either 8.5 Gy [13] or, as shown in this d
B&MTtudy, 10-Gy or 13-Gy split-dose total body irradia-
ion. In regard to anergy, the B6 CD4 T-cell re-
ponse frequencies were equivalent in the ﬁrst few
ays after infusion into both the BALB.B and CXB-2
ecipients. Moreover, increased CD25 expression was
imilarly noted on proliferating B6 CD4 T cells in
oth strains of mice. Finally, the ﬁnding of a similar
egree of CD4 T-cell inﬁltration and injury in the
ingual epithelium of both recipient strains was evi-
igure 7. GVHD potential of B6 anti-BALB.B and anti–CXB-2
hared V10 and V12 CD4 T-cell responses. BALB.B and
XB-2 mice were lethally irradiated and injected with 2  106 B6
TBM cells alone or in combination with 2  107 unseparated B6
D4 T cells, an equal number of V10- and V12-depleted
V10/12) CD4 T cells, 8.6  105 V10- and V12-enriched
V10/12) CD4 T cells (mean purity, 89%), or 5.2  105
5-enriched (V5) CD4 T cells (purity, 99%). A, Survival of
ransplanted recipients (BALB.B CD4 versus BALB.B V10/12,
 .02). B, Body weights for each group normalized as the mean
EM percentage initial body weight during sequential 1-week pe-
iods (CXB-2 V10/12 versus CXB-2 ATBM, P  .05 at all time
oints; BALB.B V10/12 versus BALB.B ATBM, P .003, weeks
-15). Data were combined from 3 similar experiments.ence of the development of a fully activated T-cell
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1henotype. Our ﬁndings are in contrast to the study
y Gonzalez et al. [40], which involved the co-transfer
f CD4 and CD8 TCR transgenic T cells into
emiallogeneic (BALB/c  B6)F1 recipients. They
lso found donor T-cell expansion without progres-
ion to acute GVHD but found that anergy was
esponsible and correlated with a large T-cell sub-
opulation that proliferated slowly, lacked CD25
xpression, and never acquired full activation pheno-
ype. We did not see evidence of these anergic char-
cteristics in the B6 CD4 T-cell response in the
XB-2 recipients.
It is interesting to note that there was a preferen-
ial homing of B6 CD4 T cells to the intestinal
pithelium of BALB.B compared with CXB-2 recipi-
nts, which was also reﬂected by an increase in crypt
ell apoptotic injury in BALB.B mice (Figure 5). In-
estinal injury is thought to play a fundamental role in
ystemic GVHD pathology in MHC-disparate models
41]. We propose an equally important role for a
hreshold level of sustained intestinal injury in sys-
emic GVHD severity across miHA barriers as well,
ecause compared with equivalent levels of epithelial
nﬁltration, severe disease in the BALB.B recipients
orrelated speciﬁcally with the greater level of intes-
inal inﬁltration and injury in these recipient animals.
An interesting correlation with the exacerbated
ut GVHD in BALB.B recipients is the increased
poptotic injury in their lingual epithelium compared
ith CXB-2 recipients, despite equal levels of CD4
-cell inﬁltration at this site (Figure 4). Increased
erum tumor necrosis factor (TNF)- levels have been
learly associated with increased GVHD intestinal
njury [10,41]. Thus, 1 possible explanation is that the
ncreased intestinal CD4 T-cell inﬁltration and re-
ultant injury in BALB.B recipients resulted in height-
ned serum levels of TNF-, which resulted in con-
iderably more systemic target tissue injury. This is
upported by earlier observations of reduced skin ep-
thelial injury after HCT after the injection of anti–
NF--blocking antibodies in another CD4 T cell–
ediated miHA GVHD model (B10.D23DBA/2)
42].
A number of studies have previously demonstrated
he selected expansion of TCR V families coincident
ith the onset of GVHD [19,24,43-47]; the relative
eterogeneity in V involvement is a reﬂection of the
ize and diversity of the allogeneic T-cell response. In
ne of our earlier investigations, TCR V CDR3-size
pectratype analysis revealed the involvement of 11
 families (V 2, 4, and 6-14) in the B6 CD4T-cell
esponse detected in the TDL of BALB.B recipients
19]. In addition, all but V2 and V11 were also
nvolved in the B6 anti–CXB-2 response. The current
nding that selective depletion of V2 and V11
6 CD4 T cells from donor inoculum effectively
iminishes GVHD development in BALB.B recipi- e
02nts supports the hypothesis that miHA-speciﬁc T
ells deﬁned within these 2 V families play a deter-
ining role in the level of disease severity in these
nimals. This notion is also strongly substantiated by
he observation that V2- and V11-enriched B6
D4 T cells were able to mediate as severe a level of
VHD as unseparated CD4 T cells (Figure 6). In
ontrast, V10 and V12 reactive cells, found to be
xpanded in both the B6 anti-BALB.B and anti–
XB-2 responses, were far less effective mediators of
evere GVHD (Figure 7).
It is possible that the V2 and V11 T cells
epresent clonal or oligoclonal responses to more than
miHA uniquely expressed by BALB.B recipients; the
nique nature of miHA expression could be related to
ts presence in certain relevant tissues. In vitro studies
sing B6 CD4 T-cell hybridomas raised against
ALB.B stimulators identiﬁed a minimum of 6 inde-
endently segregating class II–restricted miHAs, only
alf of which were also presented by CXB-2 stimula-
or cells [48]. It is unclear, however, to what extent
iHA responses observed in vitro are relevant to the
nduction of GVHD in vivo. Indeed, results from the
nduction of GVHD across a panel CXB recombinant
nbred interstrain combinations suggested the mini-
al involvement of 2 distinct miHAs in the
63BALB.B lethal GVHD response [49]. At least 1
lass II–restricted miHA (GVH-1) seemed to be
hared between BALB.B and CXB-2 strains, which
ikely stimulated the helper CD4 T-cell response
ecessary for the development of CD8 T cell–medi-
ted GVHD in both recipients. A minimum of 1 other
iHA (GVH-2) was uniquely expressed by BALB.B
ecipients and was associated with the development of
D4 T cell–mediated lethal GVHD in this strain.
he ﬁnding in Figure 1C that B6 CD4 T cells
resensitized against BALB.B miHAs (GVH-1 and -2)
emained incapable of mediating signiﬁcant GVHD
n CXB-2 recipients suggests the absence of the
ALB.B-associated GVH-2 miHA in these mice.
oreover, CXB-2 CD4 T cells can readily induce
ethal GVHD in BALB.B recipients, clearly indicating
he potency of these unique miHAs [49]. Evidence
hat such a focused number of miHAs are necessary
or the severe GVHD response in BALB.B recipients
s striking considering the original estimation of no
ess than 29 miHA loci differences between the B6 and
ALB/c parental strains [50]. The results presented in
his study lend support to the hypothesis that the
apacity of CD4 T cells to mediate a severe level of
VHD across this multiple-miHA barrier may largely
epend on the response to only a limited number of
iHAs, ie, those that stimulate the V2 and V11
esponses. Currently it is unclear which of these 2 V
amily responses are most important to severe GVHD
n this model, although results from a preliminary
xperiment have already demonstrated lethal GVHD
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V-Associated Anti-miHA CD4 T-Cell Responses
Bfter the infusion of a highly enriched V11 popu-
ation. Future experiments to distinguish between the
2 and V11 responses will allow us to narrow the
ocus toward the identiﬁcation of relevant target
iHA.
The mechanism by which B6 V2 and V11
-cell responses affect the level of GVHD severity is
n area of ongoing research. Although we cannot rule
ut differences in the expression levels of gut endo-
helial trafﬁcking molecules, such as MadCAM-1, for
xplaining the differences in intestinal inﬁltration and
njury between BALB.B and CXB-2 recipients, a more
ikely possibility is the preferential homing of B6
2 and V11 CD4 T cells in the BALB.B mice
o this site because of the tissue-speciﬁc expression of
iHA. The idea of tissue-speciﬁc homing by alloac-
ivated T cells is heavily supported by the observed
verrepresentation of particular V families in the
kin and liver of some allogeneic bone marrow trans-
lantation patients, as well as in some experimental
VHD models [19,43,44,46,47]. Alternatively, inter-
ction with their particular cognate miHA may elicit
ifferential effector functions important for acute
VHD, such as inﬂammatory cytokine production
10,51,52] or the expression of FasL and/or perforin
nd granzymes [53-56]. Such selective effector matu-
ation based on speciﬁc TCR/antigen/MHC interac-
ions have been observed in partial agonist systems
ith both CD4 and CD8 T cells [57,58]. In addi-
ion, other host-related factors may be relevant for the
ecreased GVHD severity in the intestinal tissue of
XB-2 mice. One such factor is the increased expres-
ion of mucosal extracellular matrix components, such
s tenascin, which has been shown to help protect
gainst GVHD-mediated mucosal damage and is in-
olved in tissue regeneration and repair [59].
Because both BALB.B recipients of V2/V11-
epleted B6 CD4 T cells and CXB-2 recipients of
resensitized B6 CD4 T cells still develop a signiﬁ-
ant level of acute cachexia, the other speciﬁcities of T
ells denoted by V spectratype analysis (eg, the V10
nd V12 responses) are still capable of causing some
mmunopathologic tissue injury. It would certainly be
f interest to further investigate the range of effector
echanisms used and the scope of the miHA being
ecognized by the varied V-associated responses,
articularly in comparison to that of the V2/V11
D4 T-cell responses.
In summary, as compared with the clonal fre-
uency of the donor B6 allogeneic response and the
trength of superantigen stimulation, severe GVHD
n BALB.B recipients best correlates with the presence
f V2 and V11 T cells, even in the context of a
iverse oligoclonal response. These data lend support
o previous studies that have demonstrated acute
VHD mediated by a conserved T-cell response
gainst a limited number of immunodominant miHAs 1
B&MT45,60]. Further deﬁnition of these unique responses
ay provide insight into the immunobiology of
VHD development and lead to applicable interven-
ion approaches to reduce the risk level associated
ith allogeneic HCT.
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